Lacosamide isothiocyanate-based agents: Novel agents to target and identify lacosamide receptors

Journal of Medicinal Chemistry

Volumn 52, Issue 21, 2009, Pages 6897-6911

  Ki, Duk Park ^a   Morieux, Pierre ^a   Salomé, Christophe ^a   Cotten, Steven W ^a   Reamtong, Onrapak ^b   Eyers, Claire ^b   Gaskell, Simon J ^b   Stables, James P ^c   Liu, Rihe ^a,d   Kohn, Harold ^a,e  

^a University of North Carolina   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HARKOSERIDE; ISOTHIOCYANIC ACID; N (4 ISOTHIOCYANATO)BENZYL 2 ACETAMIDO 3 (PROP 2 YNYLOXY)PROPIONAMIDE; PROTEOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL LYSATE; CONTROLLED STUDY; CYCLOADDITION; DRUG STRUCTURE; DRUG SYNTHESIS; MOUSE; NONHUMAN; PROTEIN INTERACTION; SEIZURE; STEREOISOMERISM; WESTERN BLOTTING;

ACETAMIDES; ANIMALS; ANTICONVULSANTS; BRAIN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOTHIOCYANATES; MALE; MICE; MICE, INBRED ICR; NERVE TISSUE PROTEINS; PROTEOME; SEIZURES; SERINE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 71049143243     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9012054     Document Type: Article

References (88)

1. Hauser, W. A.; Annegers, J. F.; Kurland, L. T. The prevalence of epilepsy in Rochester, Minnesota, 1940-1980. Epilepsia 1991, 32, 429-445.
2. Evans, J. H. Post-traumatic epilepsy. Neurology 1962, 12, 665-674.
3. Lindsay, J. M. Genetics and epilepsy. Epilepsia 1971, 12, 47-54.
4. (a) Rogawski, M. A.; Porter, R. J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising development stage compounds. Pharmacol. Rev. 1997, 42, 223-286.
5. (b) McNamara, J. O. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed.; Hardman, J. G.; Limbird, L. E., Eds.; McGraw-Hill: New York, 2001; Chapter 21, pp 521-547.
6. (c) Aiken, S. P.; Brown, W. M. Treatment of epilepsy: existing therapies and future developments. Front. Biosci. 2000, 5, 124-152.
7. Brodie, M. J.; Dichter, M. A. Antiepileptic drugs. N. Engl. J. Med. 1996, 334, 168-175.
8. Dichter, M. A.; Brodie, M. J. New antiepileptic drugs. N. Engl. J. Med. 1996, 334, 1583-1590.
9. (a) McCorry, D.; Chadwick, D.; Marson, A. Current drug treatment of epilepsy in adults. Lancet Neurol. 2004, 3, 729-735. (Pubitemid 39535258)
10. (b) Duncan, J. S. The promise of new antiepileptic drugs. Br. J. Clin. Pharmacol. 2002, 53, 123-131.
11. (c) Bauer, J.; Reuber, M. Medical treatment of epilepsy. Expert Opin. Emerging Drugs 2003, 8, 457-467.
12. (d) Mattson, R. H.; Cramer, J. A.; Collins, J. F.; Smith, D. B. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N. Engl. J. Med. 1985, 313, 145-151.
13. Pellock, J. M.; Willmore, L. J. A rational guide to monitoring in patients receiving anticonvulsants. Neurology 1991, 41, 961-964.
14. Cortes, S.; Liao, Z.-K; Watson, D.; Kohn, H. Effect of structural modification of the hydantoin ring on anticonvulsant activity. J. Med. Chem. 1985, 28, 601-606.
15. Conley, J. D.; Kohn, H. Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy. J. Med. Chem. 1987, 30, 567-574.
16. Kohn, H.; Conley, J. D. New antiepileptic agents. Chem. Br. 1988, 24, 231-234.
17. Kohn, H.; Conley, J. D.; Leander, J. D. Marked stereospecificity in a new class of anticonvulsants. Brain Res. 1988, 457, 371-375.
18. Kohn, H.; Sawhney, K. N.; LeGall, P.; Conley, J. D.; Robertson, D. W.; Leander, J. D. Preparation and anticonvulsant activity of a series of functionalized α-aromatic and α-heteroaromatic amino acids. J. Med. Chem. 1990, 33, 919-926.
19. Kohn, H.; Sawhney, K. N.; LeGall, P.; Robertson, D. W.; Leander, J. D. Preparation and anticonvulsant activity of a series of functionalized α-heteroatom-substituted amino acids. J. Med. Chem. 1991, 34, 2444-2452.
20. Kohn, H.; Sawhney, K. N.; Bardel, P.; Robertson, D. W.; Leander, J. D. Synthesis and anticonvulsant activities of α-heterocyclic α-acetamido-N-benzylacetamide derivatives. J. Med. Chem. 1993, 36, 3350-3360.
21. Bardel, P.; Bolanos, A.; Kohn, H. Synthesis and anticonvulsant activities of α-acetamido-N-benzylacetamide derivatives containing an electron-deficient α-heteroaromatic substituent. J. Med. Chem. 1994, 37, 4567-4571.
22. Kohn, H.; Sawhney, K. N.; Robertson, D. W.; Leander, J. D. Anticonvulsant properties of N-substituted α,α-diamino acid derivatives. J. Pharm. Sci. 1994, 83, 689-691.
23. Choi, D.; Stables, J. P.; Kohn, H. Synthesis and anticonvulsant activities of N-benzyl-2-acetamidopropionamide derivatives. J. Med. Chem. 1996, 39, 1907-1916.
24. Perucca, E.; Yasothan, U.; Clincke, G.; Kirkpatrick, P. Lacosamide. Nat. Rev. Drug Discovery 2008, 7, 973-974.
25. Stoehr, T.; Kupferberg, H. J.; Stables, J. P.; Choi, D.; Harris, R. H.; Kohn, H.; Walton, N.; White, H. S. Lacosamide, a novel anticonvulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 2007, 74, 147-154.
26. Beyreuther, B.; Freitag, J.; Heers, C.; Krebsfaenger, N.; Scharfenecker, U.; Stoehr, T. Lacosamide: a review of preclinical properties. CNS Drug Rev. 2007, 13, 21-42.
27. (a) Errington, A. C.; Stohr, T.; Heers, C.; Lees, G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol. 2008, 73, 157-169.
28. (b) Sheets, P. L.; Heers, C.; Stoehr, T.; Cummins, T. R. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide, lidocaine and carbamazepine. J. Pharmacol. Exp. Ther. 2008, 326, 89-99.
29. (a) Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discovery 2004, 3, 353-359.
30. (b) Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 2008, 51, 347-372.
31. (a) Brunton, L. L.; Lazo, J. S.; Parker, K. L. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed.; McGraw-Hill: NewYork, 2006.
32. (b) Errington,A. C.; Stoehr, T.; Lees, G.Voltage-gated ion channels: targets for anticonvulsant drugs. Curr. Top. Med. Chem. 2005, 5, 15-30.
33. (a) Saxon, E.; Bertozzi, C. R. Cell surface engineering by a modified Staudinger reaction. Science 2000, 287, 2007-2010.
34. (b) Speers, A. E.; Cravatt, B. F. Chemical strategies for activity-based proteomics. ChemBioChem. 2004, 5, 41-47.
35. (c) Ovaa, H.; van Swieten, P. F.; Kessler, B. M.; Leeuwenburgh, M. A.; Fiebiger, E.; van den Nieuwendijk, A. M. C. H.; Galardy, P. J.; van der Marel, G. A.; Ploegh, H. L.; Overkleeft, H. S. Chemistry in living cells: detection of active proteasomes by a two-step labeling strategy. Angew. Chem., Int. Ed. 2003, 42, 3626-3629.
36. (d) Kho, Y.; Kim, S. C.; Jiang, C.; Barma, D.; Kwon, S. W.; Cheng, J.; Jaunbergs, J.; Weinbaum, C.; Tamanoi, F.; Falck, J.; Zhao, Y. A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 12479-12484.
37. (a) Evans, M. J.; Saghatelian, A.; Sorensen, E. J.; Cravatt, B. F. Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat. Biotechnol. 2005, 23, 1303-1307.
38. (b) Hosoya, T.; Hiramatsu, T.; Ikemoto, T.; Nakanishi, M.; Aoyama, H.; Hosoya, A.; Iwata, T.; Maruyama, K.; Endo, M.; Suzuki, M. Novel bifunctional probe for radioisotope-free photoaffinity labeling: compact structure comprised of photospecific ligand ligation and detectable tag anchoring units. Org. Biomol. Chem. 2004, 2, 637-641.
39. (c) Ballell, L.; van Scherpenzeel, M.; Buchalova, K.; Liskamp, R. M. J.; Pieters, R. J. A new chemical probe for the detection of the cancer-linked galectin-3. Org. Biomol. Chem. 2006, 4, 4387-4394.
40. (d) Gubbens, J.; Ruijter, E.; De Fays, L. E. V.; Damen, J. M. A.; de Kruijff, B.; Slijper, M.; Rijkers, D. T. S.; Liskamp, R. M. J.; de Kroon, A. I. P. M. Photocrosslinking and click chemistry enable the specific detection of proteins interacting with phospholipids at the membrane interface. Chem. Biol. 2009, 16, 3-14.
41. (e) Staub, I.; Sieber, S. A. β-Lactam probes as selective chemical-proteomic tools for the identification and functional characterization of resistance associated enzymes in MRSA. J. Am. Chem. Soc. 2009, 131, 6271-6276.
42. (a) Takemori, A. E.; Portoghese, P. S. Affinity labels for opioid receptors. Annu. Rev. Pharmacol. Toxicol. 1985, 25, 193-223.
43. (b) Robertson, J. G. Mechanistic basis of enzyme-targeted drugs. Biochemistry 2005, 44, 5561-5571.
44. (c) Drahl, C.; Cravatt, B. F.; Sorensen, E. J. Protein-reactive natural products. Angew. Chem., Int. Ed. 2005, 44, 5788-5809.
45. Walle, T.; Walle, U. K. Pharmacokinetic parameters obtained with racemates. TIPS 1986, 155-158.
46. Ariëns, E. J. Stereochemistry: a source of problems in medicinal chemistry. Med. Res. Rev. 1986, 6, 451-466.
47. Levy, R. H.; Mattson, R.; Meldrum, B. Antiepileptic Drugs, 4th ed.; Raven Press: New York, 1995; pp 99-110.
48. (a) de Costa, B. R.; Rothman, R. B.; Bykov, V.; Jacobson, A. E.; Rice, K. C. Selective and enantiospecific acylation of κ opioid receptors by (1S,2S)-trans-2-isothiocyanato-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] -benzeneacetamide. Demonstration of κ receptor heterogeneity. J. Med. Chem. 1989, 32, 281-283.
49. (b) Burke, T. R., Jr.; Jacobson, A. E.; Rice, K. C.; Silverton, J. V.; Simonds,W. F.; Streaty, R. A.; Klee, W. A. Probes for narcotic receptor mediated phenomena. 12. cis-(+)-3-Methylfentanyl isothiocyanate, a potent site-directed acylating agent for δ opioid receptors. Synthesis, absolute configuration, and receptor enantioselectivity. J. Med. Chem. 1986, 29, 1087-1093.
50. (c) de Costa, B. D.; Rothman, R. B.; Bykov, V.; Band, L.; Pert, A.; Jacobson, A. E.; Rice, K. C. Probes for narcotic receptor mediated phenomena. 17. Synthesis and evaluation of a series of trans- 3,4-dichloro-N-methyl-N-[2- (1-pyrrolidinyl)cyclohexyl]benzeneacetamide (U50,488) related isothiocyanate derivatives as opioid receptor affinity ligands. J. Med. Chem. 1990, 33, 1171-1176.
51. (d) de Costa, B. R.; Rothman, R. B.; Bykov, V.; Jacobson, A. E.; Rice, K. C. Selective and enantiospecific acylation of κ opioid receptors by (1S,2S)-trans- 2-isothiocyanato-N-methyl-N-[2,(1-pyrrolidinyl)cyclohexyl] benzeneacetamide. Demonstration of κ receptor heterogeneity. J. Med. Chem. 1989, 32, 281-283.
52. deCosta,B.R.;Lewin,A.H.;Rice,K.C.; Skolnick, P.; Schoenheimer, J. A. Novel site-directed affinity ligands for GABA-gated chloride channels: synthesis, characterization, and molecular modeling of 1-(isothiocyanatophenyl)- 4-tert-butyl-2,6,7-trioxabicyclo[2.2.2]octanes. J.Med. Chem. 1991, 34, 1531-1538.
53. Williams, E. F.; Rice, K. C.; Paul, S. M.; Skolnick, P. Heterogeneity of benzodiazepine receptors in the central nervous system demonstrated with kenazepine, an alkylating benzodiazepine. J. Neurochem. 1980, 35, 591-597. (Pubitemid 10046887)
54. (a) Rice, K. C.; Jacobson, A. E.; Burke, T. R., Jr.; Bajwa, B. S. Irreversible ligands with high selectivity toward μ or δ opiate receptors. Science 1983, 220, 314-316.
55. (b) Lessor, R. A.; Rice, K. C.; Streaty, R. A.; Klee, W. A.; Jacobson, A. E. Probes for narcotic receptor mediated phenomena. 10. Irreversibly ligands to opioid receptors based on biologically potent endoethenooripavines. Reversible binding of fit to mu and delta opioid receptors. Neuropeptides 1984, 5, 229-232.
56. (a) Burke, T. R., Jr.; Bajwa, B. S.; Jacobson, A. E.; Rice, K. C.; Streaty, R. A.; Klee, W. A. Probes for narcotic receptor mediated phenomena. 7. Synthesis and pharmacological properties of irreversible ligands specific for μ or δ opiate receptors. J. Med. Chem. 1984, 27, 1570-1574.
57. (b) Burke, T. R., Jr.; Jacobson, A. E.; Rice, K. C.; Silverton, J.V.; Simonds,W. F.; Streaty,R. A.; Klee,W. A. Probes for narcotic receptor mediated phenomena. 12. cis-(+)-3-Methylfentanyl isothiocyanate, a potent site-directed acylating agent for δ opioid receptors. Synthesis, absolute configuration, and receptor enantioselectivity. J. Med. Chem. 1986, 29, 1087-1093.
58. 3H-diazepam binding to benzodiazepine receptors. Nature (London) 1979, 278, 854-855.
59. Perret, P.; Sarda, X.; Wolff, M.; Wu, T.-T.; Bushey; Goeldner, M. Interaction of non-competitive blockers within the γ-aminobutyric acid type A chloride channel using chemical reactive probes as chemical sensors for cysteine mutants. J. Biol. Chem. 1999, 274, 25350-25354.
60. Shelton, R. L.; Langdon, R. G. Location of the maltose isothiocyanate binding site on the human erythrocyte glucose transporter. Biochemistry 1985, 24, 2397-2400.
61. Morse, K. L.; Fournier, D. J.; Li, X.; Grzybowska, J.; Makriyannis, A. A novel electrophilic high affinity irreversible probe for the cannabinoid receptor. Life Sci. 1995, 56, 1957-1962.
62. Daphne, A.; Plotek, Y.; Miskin, I. An affinity label for α2-adrenergic receptors in rat brain. Eur. J. Biochem. 1982, 126, 537-541.
63. Soskic, V.; Maelicke, A.; Petrovic, G.; Ristic, B.; Petrovic, J. Synthesis of some phenothiazine derivatives as potential affinity ligands for the central dopamine receptors. J. Pharm. Pharmacol. 1991, 43, 27-31.
64. Casalotti, S. O.; Kozikowski, A. P.; Fauq, A.; Tuckmantel, W.; Krueger, K. E. Design of an irreversible affinity ligand for the phencyclidine recognition site on N-methyl-D-aspartate-type glutamate receptors. J. Pharmacol. Exp. Ther. 1992, 260, 21-28.
65. (a) LeTiran, A.; Stables, J. P.; Kohn, H. Design and evaluation of affinity labels of functionalized amino acid anticonvulsants. J. Med. Chem. 2002, 45, 4762-4773.
66. (b) Kohn, H.; Robertson, D. W.; Leander, J. D. Unpublished results.
67. Bucciarelli, M.; Forni, A.; Moretti, I.; Prati, F.; Torre, G. Regioselectivity of ring-opening reactions of optically active N-acetyl- 2-methoxycarbonylaziridine. Tetrahedron: Asymmetry 1995, 6, 2073-2080.
68. (a) Larsson, U.; Carlson, R. Synthesis of amino acids with modified principal properties 2: amino acids with polar side chains. Acta Chem. Scand. 1994, 48, 511-516.
69. (b) Belohradsky, M.; Ridvan, L.; Zavada, J. Synthesis of homochiral acyclic mono- and bis(alpha-amino acids) with oligo(oxyethylene) chains. Collect. Czech. Chem. Commun. 2003, 68, 1319-1328.
70. (a) Anderson, G. W.; Zimmerman, J. E.; Callahan, F. M. A reinvestigation of the mixed carbonic anhydride method of peptide synthesis. J. Am. Chem. Soc. 1967, 87, 5012-5017.
71. (b) Kunishima, M.; Kawachi, C.; Monta, J.; Terao, K.; Iwasaki, F.; Tani, S. 2-(4,6- Dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride: an efficient condensing agent leading to the formation of amides and esters. Tetrahedron 1999, 55, 13159-13170.
72. (a)Kim, S.; Yi,K.Y.Di-2-pyridyl thiocarbonate.Anew reagent for the preparation of isothiocyantes and carbodiimides. Tetrahedron Lett. 1985, 26, 1661-1664.
73. (b) Potashman, M.H.;Bready, J.; Coxon,A.; DeMelfi, T. M.; DiPietro, L.; Doerr, N.; Elbaum, D.; Estrada, J.; Gallant, P.; Germain, J.; Gu, Y.; Harmage, J.; Kaufman, S. A.; Kendall, R.; Kim, J. L.; Kumar, G. N.; Long,A.M.; Neervannan, S.; Patel, V. F.; Polverino, A.; Rose, P.; van der Plas, S.; Whittington, D.; Zanon, R.; Zhao, H. Design, synthesis, and evaluation of orally active benzimidazoles and benxoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. J. Med. Chem. 2007, 50, 4351-4373.
74. For comparable procedures for resolving stereoisomers, see the following: (a) Weisman, G. R. In Asymmetric Synthesis-Analytical Methods; Morrison, J. D., Ed.; Academic Press: New York, 1983; Vol.1, pp 153-171.
75. 1H NMR assay of the enantiomeric composition of amines and β-amino alcohols using O-acetyl mandelic acid as a chiral solvating agent. Tetrahedron 1987, 43, 5431-5456.
76. Barton, M. E.; Klein, B. D.; Wolff, H. H.; White, H. S. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001, 47, 217-227.
77. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew. Chem., Int. Ed. 2002, 41, 2596-2599.
78. Tornoe, C. W.; Christensen, C.; Meldal, M. Peptidotriazoles on solid phases [1,2,3]-triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org. Chem. 2002, 67, 3057-3064.
79. (a) Park, K. D.; Liu, R.; Kohn, H. Useful tool for biomolecule isolation, detection, and identification: acylhydrazone-based cleavable linker. Chem. Biol. 2009, 16, 763-772.
80. (b) Sun, X.-L.; Stabler, C. L.; Cazalis, C. S.; Chaikof, E. L. Carbohydrate and protein immobilization onto solid surfaces by sequential Diels-Alder and azide-alkyne cycloadditions. Bioconjugate Chem. 2006, 17, 52-57.
81. Speers, A. E.; Cravatt, B. F. Profiling enzyme activities in vivo using click chemistry methods. Chem. Biol. 2004, 11, 535-546.
82. Zhang, Z.; Ottens, A. K.; Sadasivan, S.; Kobeissy, F. H.; Fang, T.; Hayes, R. L.; Wang, K. K. W. Calpain-mediated collapsing response mediator protein-1, -2, and -4 proteolysis after neurotoxic and traumatic brain injury. J. Neurotrauma 2007, 24, 460-472.
83. Ross, P. L.; Huang, U. N.; Marchese, J. N.; Williamson, B.; Parker, K.; Hattan, S.; Khainovski, N.; Pillai, S.; Dey, S.; Daniels, S.; Purkayastha, S.; Juhasz, P.; Martin, S.; Bartlet-Jones, M.; He, F.; Jacobson, A.; Pappin, D. J. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3, 1154-1169.
84. Cotten, S.; Liu, R. Unpublished data.
85. Morieux, P.; Stables, J. P.; Kohn, H. Synthesis and anticonvulsant activities of N-benzyl (2R)-2-acetamido-3-oxysubstituted propionamide derivatives. Bioorg. Med. Chem. 2008, 16, 8968-8975.
86. Salome, C.; Salome-Grosjean, E.; Park, K. D.; Morieux, P.; Swendiman, R. ; DeMarco, E.; Stables, J. P.; Kohn, H. Unpublished data.
87. Stables, J. P.; Kupferberg, H. J. In Molecular and Cellular Targets for Antiepileptic Drugs; Avanzini, G., Tanganelli, P., Avoli, M., Eds.; John Libbey: London, 1977; pp 191-198.
88. Krall, R. L.; Penry, J. K.; Kupferberg, H. J.; Swinyard, E. A. Antiepileptic drug development: I. History and a program for progress. Epilepsia 1978, 19, 393-408.